Case Series
Successful Treatment of Pediatric Refractory/Relapsed AML with KIR-Ligand-Mismatched Cord Blood Transplant after FLAG-IDA Reinduction Therapy with or without the GO Regimen

Daisuke Toyama, Ryosuke Matsuno, Yumiko Sugishita, Ryota Kaneko, Naoko Okamoto, Masaya Koganesawa, Sachio Fujita, Kosuke Akiyama, Keiichi Isoyama, and Shohei Yamamoto

Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan

Correspondence should be addressed to Shohei Yamamoto; shohei-y@med.showa-u.ac.jp

Received 19 September 2019; Revised 11 January 2020; Accepted 25 January 2020; Published 12 February 2020

Academic Editor: Chihaya Imai

Copyright © 2020 Daisuke Toyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Prognosis in pediatric patients with refractory/relapsed acute myeloid leukemia (AML) is grim, and there is no standard treatment for such patients. Combined treatment with intensive chemotherapy and gemtuzumab ozogamicin (GO), a monoclonal anti-CD33 antibody conjugated with calicheamicin, is useful as reinduction therapy in refractory/relapsed AML. Here, we describe three cases of pediatric refractory/relapsed AML that were successfully managed with FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin), with or without GO, as reinduction therapy before a KIR-ligand-mismatched cord blood transplant. This strategy relies on the fact that killer cell immunoglobulin-like receptors (KIR) on cord blood natural killer (NK) cells recognize human leukocyte antigen (HLA) class I alleles, and that donor KIR-ligand incompatibility may be associated with lower incidence of relapse and improved survival in AML, as cells that lack these inhibitory HLA ligands can activate NK cells. All three patients are currently alive and have been disease-free for 24–65 months, although one patient developed severe sinusoidal obstructive syndrome (SOS). Thus, our strategy can result in excellent outcomes in pediatric patients with refractory/relapsed AML.

1. Introduction

Outcomes in children with refractory/relapsed acute myeloid leukemia (AML) are extremely poor [1]. Fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin (FLAG-IDA) is a commonly used reinduction regimen in AML patients [2], and FLAG-IDA combined with gemtuzumab ozogamicin (GO) is a feasible reinduction regimen for relapsed AML [3, 4]. Killer cell immunoglobulin-like receptor (KIR)-ligand incompatibility is thought to be associated with reduced incidence of relapse and better leukemia-free survival [5, 6] because clinically beneficial graft versus leukemia effects might be mediated by donor-recipient inhibitory KIR-mismatched natural killer (NK) cells [7]. Here, we describe the cases of three patients with pediatric refractory/relapsed AML who were treated using the FLAG-IDA regimen, with or without GO, as a reinduction therapy before KIR-ligand-mismatched cord blood transplant (KIR-CBT).

2. Case Presentations

Between April 2011 and December 2015, one male and two female pediatric patients with relapsed or refractory AML were treated with one course of FLAG-IDA, with or without GO, after which they underwent KIR-CBT. Patient characteristics are listed in Table 1. All three patients displayed one or more poor prognostic factors, as identified by previous studies [1, 8]. One patient (case 1) suffered from refractory (induction failure) AML, while the other two (cases 2 and 3) had relapsed AML. Among the 2 cases of relapsed AML, case 2 underwent HSCT after the first
complete remission (1 CR) because she had a high-risk karyotype (5q-), while case 3 suffered an early relapse. Cases 1 and 3 were administered FLAG-IDA with GO as reinduction therapy prior to KIR-CBT, while case 2 was given only FLAG-IDA as only 18% of her leukemic cells expressed CD33. The FLAG-IDA protocol comprised 30 mg/m² fludarabine and 2 g/m² cytarabine on days 2–6, 10 mg/m² idarubicin on day 6, and 300 µg/m² G-CSF on days 1–6. GO was administered at a dose of 3 mg/m² on day 7 of treatment, and its use was approved by the institutional review board of the Showa University Fujigaoka Hospital, Japan. All cases achieved CR after reinduction therapy (Table 1) and promptly underwent KIR-CBT (Table 2). KIR-ligand mismatching was defined based on KIR-ligand incompatibility, as initially described by Leung [9]. All three patient-donor pairs were KIR-ligand-incompatible in the graft-versus-host (GVH) direction and were all donor-mismatched for KIR2DL1 with HLA-C missing from the

### Table 1: Characteristics of the three patients with pediatric refractory/relapsed acute myeloid leukemia.

|                        | Case 1     | Case 2     | Case 3     |
|------------------------|------------|------------|------------|
| Age of induction failure or relapse/gender | 2 years/female | 18 years/female | 13 years/male |
| Diagnosis (FAB classification) | M2         | M0         | M2         |
| CD33 expression level (%) | 90         | 18         | 84         |
| Karyotype               | 46, XX     | 46, XX. Del (5) | 46, XY     |
| FLT3-ITD                | None       | None       | None       |
| Disease status          | Induction failure | 1st relapse | 1st relapse |
| Poor prognostic factor(s) |            |            |            |
| Induction failure       | Yes        | No         | No         |
| Age >10 years at relapse| No         | Yes        | Yes        |
| Early relapse (1 year from diagnosis) | —          | No         | Yes (11 months) |
| HSCT at 1st CR          | No         | Yes        | No         |
| Adverse cytogenetics    | No         | Yes        | No         |

FAB, French-British-American classification; HSCT, hematopoietic stem-cell transplantation; 1 CR, first complete remission; 2 CR, second complete remission, FLAG, fludarabine, cytarabine, granulocyte colony-stimulating factor; IDA, idarubicin; GO, gemtuzumab ozogamicin.

### Table 2: Characteristics of KIR-CBT in the three patients.

|                        | Case 1 | Case 2 | Case 3 |
|------------------------|--------|--------|--------|
| Disease status at HSCT  | 1 CR   | 2 CR   | 2 CR   |
| Interval between GO and HSCT (days) | 36     | —      | 56     |
| Conditioning            | TBI + CY | LPAM + Flu + TBI2Gy | TBI + CY     |
| Donor source            | UR-CB  | UR-CB  | UR-CB  |
| HLA match (DNA typing)  | 5/8 (B, C, DR) | 5/8 (B, C) | 5/8 (B, C, DR) |
| HLA-C                   | Patient: C08:01/12:03 (C1/C1) | C03:04/14:02 (C1/C1) | C03:03/07:02 (C1/C1) |
|                         | Donor:  C08:01/04:01 (C1/C2) | C01:02/04:01 (C1/C2) | C04:01/07:02 (C1/C2) |
| KIR-HLA                 | KIR2DL1 (inhibitory KIR) | KIR2DL1 (inhibitory KIR) | KIR2DL1 (inhibitory KIR) |
| GVHD direction mismatch | 6.1    | 3.2    | 2      |
| NCC (×10³/kg)           | Ursodeoxycholic acid + LMWH | Ursodeoxycholic acid + LMWH + rTM | Ursodeoxycholic acid + LMWH + rTM |
| Engraftment             | Day 36 | Day 32 | Day 30 |
| SOS prophylaxis         | Tacrolimus + MTX | Tacrolimus + MTX | Tacrolimus + MTX |
| SOS                     | Very severe | —       | —      |
| GVHD prophylaxis        | —      | —      | —      |
| aGVHD                   | Grade I (skin: stage 2) | Grade III (skin: stage 3, gut: stage 3) |
| cGVHD                   | Limited (skin) | —       | —      |
| Treatment of aGVHD      | PSL    | —      | PSL    |
| Infection               | —      | CMV viremia | —      |
| Prognosis               | Alive (65 months) | Alive (34 months) | Alive (24 months) |

KIR-CBT, KIR-ligand-mismatched cord blood transplant; HSCT, hematopoietic stem-cell transplantation; GO, gemtuzumab ozogamicin; HLA, human leukocyte antigen; GVH, graft-versus-host; NCC, nucleated cord blood cells; SOS, sinusoidal obstruction syndrome; GVHD, graft-versus-host disease; aGVHD, acute GVHD, cGVHD, chronic GVHD; CR, complete remission; TBI, total body irradiation; CY, cyclophosphamide; LPAM, melphalan; Flu, fludarabine; UR, unrelated; CB, cord blood; rTM, recombinant human soluble thrombomodulin; LMWH, low-molecular-weight heparin; tacrolimus; MTX, methotrexate; PSL, prednisolone; CMV, cytogenesis virus.
recipient. Cases 1 and 3 received full-intensity conditioning cyclophosphamide (120 mg/kg) and total body irradiation (TBI: 12 Gy), while case 2 received melphalan (140 mg/m²), fludarabine (125 mg/m²), and TBI (2 Gy), as this was her 2nd HSCT. Anti-thymocyte globulin (ATG) was not used in any of the patients, and tacrolimus (0.02 mg/kg/day) and short-term methotrexate were used for prophylaxis against graft-versus-host disease (GVHD). Urosodeoxycholic acid (UDCA) and low-molecular-weight heparin (LMWH) were administered for prophylaxis against sinusoidal obstruction syndrome (SOS) in case 1, while cases 2 and 3 received prophylactic recombinant human soluble thrombomodulin (rTM; 380 U/kg per day for 7 days from days 7 to 13), in addition to UDCA and LMWH [10]. All three cases underwent KIR-CBT within 2 months of reinduction therapy. In case 1, extremely severe SOS developed on day 8 which was treated with rTM; however, this was ineffective, and continuous hemodialfiltration was initiated to maintain hydration and remove any inflammatory cytokines. This resulted in a gradual improvement in her SOS by day 20. Additionally, Grade I acute GVHD (stage 2 skin rash) and limited chronic GVHD (affecting the skin alone) developed in this patient, which were successfully treated with prednisolone (PSL). Tacrolimus was suspended at 9 months after KIR-CBT. In cases 2 and 3, prophylactic rTM was successful and they did not develop SOS. In case 2, no acute or chronic GVHD occurred, and the administration of tacrolimus was stopped at 5 months after KIR-CBT. In case 3, grade III acute GVHD (stage 3 skin rash and stage 3 diarrhea) developed, and it responded well to PSL treatment. Chronic GVHD did not occur in this patient, and the administration of tacrolimus was stopped at 5 months after KIR-CBT. All three patients are currently alive without any evidence of relapse at 24–65 months after KIR-CBT.

### 3. Discussion

Prognosis in pediatric patients with refractory/relapsed AML is poor at best and known prognostic factors for poor survival include early relapse, undergoing HSCT during 1 CR, age of >10 years at relapse, and adverse cytogenetics [1]. Since April 2011, our strategy for treating patients with refractory or relapsed AML having poor prognostic factors has been one course of FLAG-IDA, with or without GO, followed by KIR-CBT. This strategy has two major implications for the treatment of pediatric patients with refractory/relapsed AML, especially those with poor prognostic factors. First, the FLAG-IDA regimen, with or without GO, might be a feasible reinduction therapy. This is because, among pediatric patients with relapsed AML, those who do not achieve 2 CR exhibit significantly lower 5-year OS rate than the patients who achieve 2 CR [1, 8]. A European study group has reported that FLAG, with or without an anthracycline, can induce 2 CR in 78% of the cases, which is an excellent rate of induction [1]. GO, a monoclonal anti-CD33 antibody conjugated with calicheamicin, has been shown to be effective in relapsed AML [11], and FLAG-IDA, combined with low-dose GO (3 mg/m²), is a feasible induction therapy option in younger patients with primary AML [3, 4]. All three of our patients also achieved CR after being treated with FLAG-IDA, with or without GO. Second, we used KIR-CBT (a type of HSCT) in pediatric refractory/relapsed AML patients with poor prognostic factors because of the following rationale. NK cells express inhibitory KIR on their surface, and NK cell alloreactivity after allogeneic transplantation is determined by the specificity of the KIR on the donor NK cells for the recipient’s MHC (major histocompatibility complex) class I antigens [12]. Ruggeri et al. were the first to report good clinical results, i.e., no relapse, rejection, or acute GVHD in AML patients who underwent HLA-mismatched transplantation involving KIR-ligand incompatibility in the GVH direction [5]. In a study wherein approximately 80% of the patients were administered ATG, Willemze et al. have reported that KIR-ligand incompatibility had a beneficial effect on outcomes after CBT [13]. In contrast, in a study in which only 30% of the patients were administered ATG, Brunstein et al. have reported that KIR-ligand incompatibility had no effect on outcomes after CBT [14]. It is possible that in vivo T-cell depletion, secondary to ATG administration, contributed to the posttransplant expansion of functional NK cells which then favored alloreactivity in the presence of KIR-ligand mismatching. Although none of our patients were given ATG, there were no relapses, and acute GVHD remained under control. This may be because many Japanese express HLA-C1 and few episodes of acute GVHD have been recorded after KIR-ligand-mismatched HSCT in Japan [15]. Rubnitz et al. have reported no relapses in pediatric AML patients who underwent KIR-ligand-mismatched HSCT after achieving CR [16]. As these results suggest that NK cell alloreactivity affects the extent of minimal residual disease, KIR-CBT should be performed as soon as possible after CR has been achieved. Although all three of our patients successfully achieved CR, evidence for the efficacy of including GO during induction therapy and KIR-CBT in pediatric AML remains inconclusive. Recent advances in AML treatment have identified several promising modalities, such as antimethylating agents, immune checkpoint inhibitors (ICIs), and chimeric antigen receptor-T cells (CAR-T). Daver et al. have reported that Azacitidine, in combination with ICIs, may be safe and effective in patients with relapsed AML [17], while Li et al. have stated that CD33 CAR-T is effective against AML cells and that it prolongs survival in a mouse xenograft model [18]. Those new drugs can alter the treatment landscape of pediatric refractory/relapsed AML and provide new treatment opportunities in the future.

In conclusion, the FLAG-IDA reinduction therapy described here, with or without GO, when used before KIR-CBT, appears to be a feasible treatment strategy in pediatric patients with refractory/relapsed AML. However, definitive conclusions about the efficacy of this approach cannot be made because of the very small number of patients included in this study. Therefore, additional prospective studies are required to evaluate the same.
Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
D. T. wrote the paper, and S. Y., R. M., Y. S., R. K., N. O., M. K., S. F., K. A., K. I, and S. Y treated the patients.

References
[1] A. Sander, M. Zimmermann, M. Dworzak et al., “Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials,” Leukemia, vol. 24, no. 8, pp. 1422–1428, 2010.
[2] Fleischhack, Hasan, Graf, Mann, and Bode, “IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial,” British Journal of Haematology, vol. 102, no. 3, pp. 647–655, 1998.
[3] W. J. Kell, A. K. Burnett, R. Chopra et al., “A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia,” Blood, vol. 102, no. 13, pp. 4277–4283, 2003.
[4] N. Yoshida, H. Sakaguchi, K. Matsumoto, and K. Kato, “Successful treatment with low-dose gemtuzumab ozogamicin in combination chemotherapy followed by stem cell transplantation for children with refractory acute myeloid leukemia,” British Journal of Haematology, vol. 158, no. 5, pp. 666–668, 2012.
[5] L. Ruggeri, M. Capanni, E. Urbani et al., “Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants,” Science, vol. 295, no. 5562, pp. 2097–2100, 2002.
[6] L. Moretta, F. Locatelli, D. Pende, E. Marcenaro, M. C. Mingari, and A. Moretta, “Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation,” Blood, vol. 117, no. 3, pp. 764–771, 2011.
[7] K. C. Hsu, C. A. Keever-Taylor, A. Wilton et al., “Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes,” Blood, vol. 105, no. 12, pp. 4878–4884, 2005.
[8] H. Nakayama, K. Tabuchi, A. Tawa et al., “Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol,” International Journal of Hematology, vol. 100, no. 2, pp. 171–179, 2014.
[9] W. Leung, “Use of NK cell activity in cure by transplant,” British Journal of Haematology, vol. 155, no. 1, pp. 14–29, 2011.
[10] S. Yamamoto, R. Matsuno, Y. Sugishita et al., “Sinusoidal obstructive syndrome prophylaxis with recombinant human soluble thrombomodulin is feasible in gemtuzumab ozogamicin-treated patients undergoing allogeneic hematopoietic cell transplantation,” Bone Marrow Transplantation, vol. 52, no. 7, pp. 1068–1070, 2017.
[11] E. L. Sievers, R. A. Larson, E. A. Stadmayer et al., “Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse,” Journal of Clinical Oncology, vol. 19, no. 13, pp. 3244–3254, 2001.